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LDHa b s t r a c t
Objectives: The study aimed to evaluate the dose delivered to the heart during radiotherapy of left-sided
and right-sided breast cancer (BC) patients, correlate the dose and laterality of radiotherapy to the pos-
sible cardiac damage and evaluate whether Left-ventricular Ejection Fraction (LVEF), Troponin-I (TnI),
Creatinine Kinase (CK), Creatine Kinase-MB Relative Index (CK-MBRI) or Lactic Dehydrogenase (LDH)
could be used to detect the possible onset of radiotherapy-related cardiotoxicity.
Subjects and methods: 80 females were assigned as; 30 left-sided BC patients, 30 right-sided BC patients
and 20 healthy females. Patients were treated by radical mastectomy followed by FAC-based chemother-
apy and radiotherapy. CT-based 3D-planning was used to generate cardiac dose-volume histograms to
assess mean dose received by the heart.
Echocardiography was done to all patients before and 1 year after completing radiotherapy. In serum,
TnI and CK-MB concentration and CK and LDH activities were determined before and 1 year after
radiotherapy.
Results: In left-sided patients, mean dose delivered to the heart was significantly higher in left-sided
patients with significant association with total radiotherapy dose in left- but not right-sided patients.
LVEF before and after radiotherapy were statistically different only in left-sided patients. LVEF one year
after radiotherapy dropped 20% or more (DLVEF) in 6 patients, all were left-sided.
Using cut-off values 0.08 ng/mL for TnI and 1.4 for CK-MBRI; 11 left-sided patients had abnormal TnI and
CK-MBRI vs 5 right-sided patients, the 6 patients identified with DLVEF  20 were all among them.
Conclusion: the mean dose delivered to the heart is significantly higher in left-sided patients, and it
was correlated to the total radiotherapy dose. One year after radiotherapy, DLVEF is possibly good
marker of cardiotoxicity onset, however, the persistent elevation of both TnI and CK-MBRI could iden-
tify both patients with cardiotoxicity and patients that are thought to be in subclinical phase of cardiac
damage.
 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer (BC) is the utmost recurring cancer type and the
2nd principal cause of cancer death in women, surpassed only by
lung cancer.1 Higher incidence rates are reported in more devel-
oped countries, but relatively higher mortality is found in develop-
ing countries because of the deficiency in early detection andaccess to treatment facilities.2 Breast cancer represented 33.5% of
all freshly diagnosed cancers in Egyptian women during the year
2014, with an age-standardized ratio of incidence of 49.5 per
100,000.3
The part played by radiotherapy is well acknowledged in every
stage of BC treatment. The most common schedules for irradiation
are 50 Gy in 25 fractions or 42 Gy in 16 fractions delivered to the
whole breast or chest wall, executed five days per week for five
weeks.4,5 Adjuvant radiotherapy for BC was able to diminish mor-
tality in many BC categories. In irradiated women, there was a sig-
nificant increase in incidence of non-breast-cancer mortality, at
least with some older radiotherapy regimens. This increase was
slight during the first 5 years, but continued after year 15. The
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1.27, which reduces the profitable effect of radiotherapy on overall
survival.6
Left ventricular ejection fraction (LVEF) estimated during
echocardiography is a crucial marker of myocardial function before
and after therapy. The main limiting factor for using echocardiog-
raphy for diagnosis is its relatively low reproducibility because of
elevated intra- and inter-observer inconsistency.7 Along with sev-
eral serum cardiac makers as Troponin I (TnI), Creatine Kinase (CK),
Creatine Kinase-MB Relative Index (CK-MBRI) and Lactic Dehydro-
genase (LDH). Although cardiac markers could confer acceptable
sensitivity, they mostly lack specificity. However, none of these
had been evaluated as a possible tool to evaluate patients undergo-
ing adjuvant therapy who might be at higher risk of therapy-
induced cardiac dysfunction or cardiotoxicity.8
The study aimed to evaluate the dose delivered to the heart dur-
ing radiotherapy of left-sided and right-sided BC patients, correlate
the dose and laterality of radiotherapy to the possible cardiac dam-
age and evaluate whether LVEF, TnI, CK, CK-MBRI or LDH could be
used to detect the possible onset of radiation-induced
cardiotoxicity.2. Patients and methods
The study included 80 females in three groups; 30 left-sided BC
patients, 30 right-sided BC patients and 20 normal healthy females
of matched age. A local ethics committee approved the study and
each subject signed an informed consent before being enrolled.
Exclusion criteria included patients with ischemic or valvulary
heart disease, baseline LVEF <50%, hypertension and cardiac tumor.
Patients were treated by modified radical mastectomy followed by
FAC-based chemotherapy, radiotherapy and hormone therapy
according to their clinical condition. Radiotherapy included isocen-
trically irradiating the chest wall by two tangential beams with
selective multi-leaf blocking to protect organs that might be at risk,
the regimen of radiation delivery used were conventional 50
Gy/25-fractions or hypo-fractionation 42 Gy/16 fractions. Internal
mammary lymph nodes (IMLN), if indicated, were included in the
tangential beams. The two arms (left- and right BC patients) were
kept balanced, where each arm contained 30 patients; 11 received
50 Gy/25 fractions and 9 received 42 Gy/16 fractions, with 8
receiving IMLN radiotherapy. Patients were followed up for 12
months after completing radiotherapy.
Radiotherapy regimen used for each patient was reconstructed
on CT-based 3D planning system. The heart and coronary arteries
were contoured, including the right atrium and excluding the pul-
monary trunk, ascending aorta and superior vena cava, with the
caudal myocardial border being the lower most heart contour.
The left main coronary artery was included with the contour of
the left anterior descending coronary artery. For every patient, car-
diac dose volume histograms were engendered to estimate the
mean dose received by the heart for all patients.
Echocardiography was done for all patients twice; before and
12 months after radiotherapy to assess LVEF (2D Simpson’s
method) before and after therapy. From each breast cancer patient,
two blood samples were obtained, before and 12 months after
completing radiotherapy. One blood sample was drawn from each
control subject to set reference normal range of the measured car-
diac markers. After sampling, sera from all samples were collected
and stored at -70 C till time of assay.
TnI in serum was assayed by the Calbio tech cardiac troponin I
ELISA kit (Calbiotech Inc., Spring Valley, CA). The TnI ELISA test is a
solid phase ELISA system that utilizes four monoclonal antibodies
that recognize distinct antigenic determinants on TnI. CK activity
in serum was determined colorimetrically by the Abcam ab155,901 creatine kinase activity assay kit (Abcam, UK). CK enzyme
catalyzes a reversible reaction between creatine and ATP to form
phosphocreatine and ADP, which react with CK Enzyme Mix to
form an intermediate. Thae intermediate reduces a colorless agent
forming a colored product with 450 nm absorbance. Also LDH
activity was measured colorimetrically by the Abcam ab 155,901
lactate dehydrogenase activity assay kit (Abcam, UK). LDH carries
out the catalysis of the reversible reaction of lactate and NAD+ to
form pyruvate and NADH. Then NADH interacts with a probe to
produce a colored product with a strong 450 nm absorbance. CK-
MB was assayed by CKMB Human ELISA Kit (Abcam, UK). Abcam’s
CKMB Human ELISA Kit is an in vitro assay for the quantitative
measurement of human CKMB in serum using two anti-CK-MB
antibodies.
Data were statistically analyzed by SPSS (Statistical Package for
the Social Sciences) software package, version 19.0 (SPSS Inc., Chi-
cago, IL, USA). Comparisons of means were made by Chi square test
or student’s paired t-test. Two-tailed p values of <0.05 were con-
sidered significant. Spearman correlation analysis was used to
assess relationships between parameters. Receiver Operating Char-
acteristic (ROC) curves were drawn for all parameters and a cut-off
level was selected for each to evaluate patients in terms of normal
or abnormal levels. These cut-offs were 0.08 ng/mL for TnI, 109 U/L
for CK, 1.4 for CK-MBRI and 287 U/L for LDH.3. Results
The study included 80 females divided into three groups; two
patients’ groups, included 30 females with right-sided BC and 30
females with left-sided BC and 20 normal healthy females match-
ing patients groups in age as a control group.
Table 1 represents the clinical characterization of the patients’
groups involved in the study. As shown, the patients’ age ranged
from 28 to 67 years with a median of 47 y. Premenopausal women
comprised 73.3% of right-sided and 63.3% of left-sided BC patients.
The major bulk of patients had a single tumor, with no significant
difference found between right and left sided BC patients conform-
ing to tumor multiplicity (p = .668). Although left-sided BC patients
had a higher prevalence of grade II tumors (93.3%) than right-sided
BC patients (76.7%), the difference was not statistically significant
(p = .145).
According to TNM staging, no significant difference was found
between right- and left-sided patients (p = 1.000). 66.7% of right-
sided BC patients and 70% of left-sided BC patients were positive
for vascular invasion, however, no significant difference existed
between the two groups (p = .781).
As shown in Fig. 1A, the mean dose delivered to the heart in
left-sided BC patients was statistically significantly higher than
that in right-sided BC patients (z = 6.668, p < .001). The radiation
dose delivered to the heart ranged from 0.3 to 0.95 Gy in right-
sided BC patients with a mean of 0.60 Gy and from 1.5 to 7.1 Gy
in left-sided BC patients with a mean of 4.46 Gy. There was a highly
significant correlation between the total dose of radiotherapy and
mean dose delivered to the heart in left-sided (rs = 0.579, p = .001)
but not in right-sided BC patients (rs = 0.189, p = .317); Fig. 1B.
Table 2 represents LVEF in right- and left-sided BC patients
comparing baseline LVEF measured before radiotherapy and that
measured one year after completion of radiotherapy. Mean base-
line LVEF was 68.4% in right-sided BC patients and 69.37% in left-
sided BC patients, while mean LVEF after radiotherapy was
66.57% in right-sided BC patients and 64.5% in left-sided BC
patients. The difference between right and left-sided BC patients
was not statistically significant according to LVEF before or after
radiotherapy (p = .645 and 0.210; respectively). In left-sided BC
patients, LVEF before and after radiotherapy were statistically dif-
Table 1
Clinical characterization of patients.















































































t: Student t-test for comparing between right and left.
P: significance when comparing left- to right-sided breast cancer patients.
v2: Chi square test.
Fig. 1. The mean dose delivered to the heart in right- and left-sided BC patients (A) and the correlation between total radiotherapy dose and mean dose delivered to heart in
each group (B). rs: Spearman coefficient, *: Statistically significant at p  .05.
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right-sided patients (p = .194). LVEF measured one year after radio-
therapy dropped 20% or more from baseline (DLVEF  20) in only 6
patients, all them were left-sided, that resulted in a statistically
significant difference between right and left-sided BC patients
regarding LVEF dropping 20% or more from baseline (p = .024). Also
the mean dose delivered to those 6 patients (6.1 Gy) was signifi-
cantly higher than the remaining 24 left-sided patients (3.9 Gy).
Fig. 2 represents the mean values of TnI, CK, CK-MBRI and LDH
in right- and left-sided BC patients and in controls. TnI levels pre-
sented as mean ± SD were 0.083 ± 0.11 and 0.078 ± 0.06 ng/mL
before and after RT in right-sided patients and 0.073 ± 0.06 and 0
.091 ± 0.055 ng/mL before and after RT in left-sided patients. All
of them were significantly different from the control level (0.02
± 0.03 ng/mL). CK values were 69.7 ± 43.5 and 68.1 ± 51.2 U/L
before and after RT in right-sided patients and 63.0 ± 38.2 and 70
.0 ± 39.4 U/L before and after RT in left-sided patients. All of them
were significantly different from the control level (93.6 ± 17.6 U/L).
CK-MBRI values were 1.32 ± 0.28 and 1.40 ± 0.31 before and after
RT in right-sided patients and 1.30 ± 0.25 and 1.51 ± 0.39 beforeand after RT in left-sided patients. All of them were significantly
different from the control level (1.03 ± 0.17). LDH levels were 37
0 ± 172 and 353 ± 198 U/L before and after RT in right-sided
patients and 371 ± 228 and 402 ± 201 U/L before and after RT in
left-sided patients. All these means were significantly different
from the control level (247 ± 34 U/L). None of the tested biochem-
ical parameters showed any significant difference between right-
and left-sided patients either before or after RT. Only CK-MBRI
was significantly higher after radiotherapy than before in left-
sided BC patients (p = .37), and not in right-sided BC patients.
ROC curves for all parameters were used to draw cut-off values
to evaluate patients in terms of normal or abnormal levels, pre-
sented in Table 3. Yet, there was no significant difference between
before and after RT either on right- or left-sided BC patients in any
of the parameters tested, except in CK-MBRI. As for CK-MBRI a sig-
nificant difference was noted between before and after radiother-
apy in left-sided but not in right-sided BC patients. In left sided-
BC patients after radiotherapy, 11 patients had abnormal TnI and
CK-MBRI vs 5 in the right-sided patients. The 6 patients identified
with DLVEF  20 were all included in those 11 patients.
Table 2
LVEF presented as M ± SD in right- versus left-sided BC patients before and after radiotherapy (RT) and the fraction of patients with LVEF drop 20%.
LVEF (%) Right-sided BC (n = 30) Left-sided BC (n = 30) Right vs left sided
Before RT 68.40 ± 6.71 69.37 ± 9.24 t = 0.464 p = 0.645
1 year after RT 66.57 ± 6.25 64.50 ± 6.64 t = 1.242 p = 0.219
Before vs after RT t1 = 1.330 p1 = 0.194 t1 = 2.440* p1 = 0.021*
DLVEF  20% 0 (0.0%) 6 (20.0%) v2 = 6.667* p = 0.024*





v2 = 20.739* p2 = 0.019*





p : significance when comparing LVEF in right- and left-sided BC patients.
t: Student t-test when comparing right- and left-sided BC patients.
p1 : significance when comparing LVEF before and 1-y after radiotherapy.
t1: Paired t-test when comparing LVEF before and 1-y after radiotherapy.
P2 : significance when comparing doses in patients with DLVEF  20% and patients with DLVEF < 20%.
v2: Chi square test.
* : Statistically significant at p  .05.
Fig. 2. mean levels of TnI (A), CK (B), CKMB-RI (C) and LDH (D) in right and left-sided BC patients and in controls before and after radiotherapy (RT). * : Significantly different
at p  .05 when compared to controls. # : Significantly different at p  .05 when comparing before and after radiotherapy.
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lated with any of the clinicopathological parameters of BC in either
right- or left-sided patients; including tumor multiplicity, tumor
size, tumor grade, lymph node involvement or vascular invasion.
Three significant correlations were found in left sided BC patients
between mean dose delivered to the heart and each of DLVEF
(r = 0.422, p = .020), TnI levels (r = 0.410, p = .031) and CK-MBRI
(r = 0.392, p = .030), however these correlations were found miss-ing in right-sided patients (r = 0.343, p = .064; r = 0.241, p = .175
and r = 0.185, p = .445; respectively), Table 4.4. Discussion
Radiotherapy is an important treatment strategy after breast
conservative surgery or after mastectomy in BC patients. For long,
Table 3
Number and percent of patients above and below cut-offs for TnI, CK and LDH.
Parameter Cut-off Right-sided BC No. (%) Left-sided BC No. (%) P1 P2 P3













































Assessed by Chi square test.
P1: significance when comparing before and after RT in right-sided BC group.
P2: significance when comparing before and after RT in left-sided BC group.
P3: significance when comparing right-sided BC group with left-sided BC group.
Table 4
Correlation between the mean doses of radiation delivered to the heart in right and
left-sided BC patients and DLVEF, TnI and CK-MBRI.
Right-sided BC Left-sided BC
r p r p
LVEF 0.343 0.064 0.422 0.020
TnI 0.241 0.175 0.410 0.031
CK-MBRI 0.185 0.445 0.392 0.030
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apy was not of concern, as the heart has traditionally been consid-
ered a radio-resistant organ that would be unaffected by doses
below 30 Gy. The severity of the problem of radiotherapy-
induced cardiac disease did not become widely recognized until
the 1990s, when randomized trials in early-stage BC proved that
radiotherapy-related cardiac damage almost completely out-
weighed its survival benefits.9 Recently, the potential problem of
radiation-induced cardiac disease has received much attention
which is contributing to attempts to reduce heart dose.10
The mechanism of radiation-induced myocardial impairment is
not thoroughly understood. It may result from the effect on
microvasculature with diffuse interstitial fibrosis, which begins
with the injury of endothelial cells within heart blood capillaries,
which leads to an acute inflammatory reaction, followed by
endothelial cells proliferation and obstruction of myocardial capil-
lary lumen. In a later stage, ischemia and myocardial cell death
result from vessel lumen obstruction and formation of thrombi,
that result in replacement of cardiac tissue by fibrotic tissue and
may lead to chronic heart failure.11,12 Radiation may cause damage
to major arteries, by inducing inflammation and oxidative damage
in large vessels. In combination with high cholesterol, that could
increase oxidation of LDL which allows them to be engulfed by
macrophages, thus triggering the atherosclerotic process.13
Myocardial cells involved with conduction may be damaged, lead-
ing to arrhythmias. Pericardium injury may emerge as excessive
pericardial effusion, fibrotic thickening, pericardial adhesions,
and pericarditis.14,15
The mean dose of radiation delivered to the heart was esti-
mated for all patients and it was significantly higher in left-sided
than in right-sided BC patients. For left-sided patients the heart
was contiguous to the tangential fields, and the average mean
heart dose was 4.46 Gy. In contrast, for the patients who received
right-sided irradiation, the heart was remote from the fields and
received only scattered dose, so the average mean heart dose
was 0.6 Gy. In a similar study, Taylor el al.16 reported an average
mean heart dose of 2.3 Gy in left-sided patients, which was muchlower than that reported in this study, and 1.5 Gy in right-sided
patients.
In the present work, a highly significant correlation was noted
between the total dose of radiotherapy and the mean dose deliv-
ered to the heart in left-sided BC patients, which implies that
increasing the total dose of radiotherapy would increase the mean
heart dose in left-sided but not in right-sided patients. Therefore,
treatment planning should consider the heart dose delivered as a
modifying factor in left-sided BC patients, so as not to deliver a
heart dose higher than the tolerable dose of various cardiac tissues.
Among the most common manifestations of radiation-driven
cardiotoxicity is the development of left ventricular dysfunction
which presents as an asymptomatic decrease in LVEF from the
baseline value measured before the beginning of treatment. LVEF
significantly decreased from baseline in left-sided breast cancer
patients after one year of completing radiotherapy, but not in
right-sided patients. This significant decrease in LVEF in left-
sided patients is thought to reflect the possible effects of radiation
on the heart. Cardiac toxicity is speculated if LVEF drops either
more than 10% from baseline to levels below 50% or 20% or more
from baseline despite still normal. It was assumed that radiation-
induced cardiac toxicity would need several years to develop.
However, in this study despite the very short follow up time of
only one year, according to the forementioned criteria, cardiac tox-
icity was assumed in 6 patients, which were all left-sided.
Several studies have investigated cardiac function in left- and
right-sided BC patients receiving radiotherapy, and their findings
were similar to the results in this study.6,10,14,16,17 The frequency
of cardiac toxicity in our study seems much lower than previous
reports, which might be related to the fact that follow up time of
our study is shorter than previous studies; some of the cardiac
injury may still be in subclinical phase and the actual cardiac dam-
age may be under evaluated.
Detectable changes in LVEF usually accompany significant func-
tional impairment, at which point the ability to regain normal car-
diac function becomes limited. Thus, the classical way for detecting
cardiotoxicity is suboptimal and there remains a need to effectively
identify patients at risk of developing serious cardiac ramifications
following radiotherapy. Radiation-induced injury develops over a
prolonged time period, making diagnosis more difficult, and the
ability of the heart to compensate may further delay injury recog-
nition for years. Many biomarkers have emerged as an alternative
approach and a promising complement to routine echocardiogra-
phy, to describe the risk of cardiac dysfunction in clinically asymp-
tomatic patients. Classic cardiac biomarkers, TnI, CK, CK-MBRI and
LDH, were investigated as possible markers of subclinical
radiation-induced cardiotoxicity.
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cantly different from controls both before and after radiotherapy,
where TnI, CK-MBRI and LDH were significantly higher and CK
was significantly diminished than their corresponding controls,
however, left- and right-sided BC patients were not significantly
different regarding any of the markers tested. Since all patients
received chemotherapy followed by radiotherapy, so it was hard
to draw exclusive conclusions regarding the effect of radiotherapy
alone and this pattern may reflect the fact that cardiac damage has
already begun as a result of chemotherapy, before radiotherapy
started.
Many biochemical parameters have been previously assessed
during and after chemotherapy to evaluate its cardiac side-
effect.8,18–22 Cardiac TnI has demonstrated clinical value in predict-
ing subsequent cardiotoxicity after high-dose chemotherapy,18,19
while decreased CK levels and elevated CK-MBRI values were
reported in breast cancer irrespective of treatment,20,21 and LDH
was reported to increase with chemotherapy.22 Since publications
dealing with radiotherapy alone are relatively scarce, only TnI had
been evaluated as a marker of radiation-induced cardiotoxicity,
with a discrepancy in results that made them hard to interpret.
In the current study, before radiotherapy all parameters were sig-
nificantly different from their normal levels, which limited their
value in detecting radiation-induced cardiac damage. Thus usage
of cutoffs was necessary.
Using the fore-mentioned cutoffs, TnI and CK-MBRI both
remained elevated 1 year after radiotherapy in 5 right-sided and
11 left-sided patients, which may reflect the onset of cardiac dam-
age in these patients. Cardiotoxicity was already confirmed by D
LVEF > 20% in 6 of them. The in 5-patients of the right-sided group
is probably more relevant to the onset of chemotherapy-induced
cardiac damage, since the dose received by the heart in this group
was quite small, but in left-sided group 11 patients showed eleva-
tion of TnI and CK-MBRI, since the effect of chemotherapy is
expected to be similar in both groups, the excess fraction in the
left-sided group is probably more connected to radiation-induced
cardiac damage. However, verification of that assumption might
require longer follow up. CK and LDH were not beneficial in pre-
dicting or recognizing patients at risk of radiation induced cardiac
damage.
In conclusion, during radiotherapy, the mean dose delivered to
the heart in left-sided BC patients is significantly higher than right-
sided BC patients (4.46 vs 0.6 Gy), and cardiac dose was correlated
to the total dose. After 1 year of completing radiotherapy, DLVEF
was a good marker to detect the onset of cardiotoxicity, however,
the persistent elevation of both TnI  0.08 ng/ml and CK-MBRI 
1.4 was a more sensitive indicator that identified both patients
with cardiotoxicity and a higher fraction of patients that are
thought to be in subclinical phase of cardiac damage either due
to chemotherapy alone or combined with radiotherapy. Neither
CK nor LDH showed any significant value in identifying patients
at risk of radiation induced cardiac damage.Conflict of interest
The authors declare that there is no conflict of interest.
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